# QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC

> **NCT07134413** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 77 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** QL1706 plus bevacizumab with or without chemotherapy

## Key facts

- **NCT ID:** NCT07134413
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2027-10
- **Final completion:** 2029-07
- **Target enrollment:** 77 (ESTIMATED)
- **Last updated:** 2025-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07134413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07134413, "QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07134413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*